AbbVie: Emerging Strong Post-Humira
Cashu Finance·4 min read

TL;DR
- AbbVie is successfully transitioning from Humira towards innovative therapies.
- Strong sales from Skyrizi and Rinvoq are driving revenue growth.
- New drug developments like ABBV-466 show promise for future blockbusters.
The Legacy of Humira and Its Decline
Humira has played a pivotal role in AbbVie's success, generating billions in revenue from its efficacy in treating autoimmune diseases. However, with the looming presence of biosimilars, which have already begun to carve out market share, AbbVie faced a sharp decline in sales, with recent reports showing revenue drop to $683 million from nearly $1 billion in the prior quarter, marking a significant 30.6% decrease. This decline underscores the pressure AbbVie is facing as it transitions from its reliance on Humira toward diversifying its portfolio.
Strategic Innovations and New Revenue Streams
The changes within AbbVie reflect a strategic pivot aimed at diminishing the adverse impact of Humira's patent expiration. The company has reported strong performances from its newer drugs, particularly Skyrizi and Rinvoq, which together generated substantial revenues, complementing its traditional offerings. Skyrizi alone brought in an impressive $5.7 billion in a recent quarter, showcasing the potential for these new drugs to fill the revenue void left by Humira. Such performance aligns with previous articles highlighting AbbVie’s robust focus on innovation, fueling confidence among investors for the long term. As mentioned in a recent analysis, AbbVie is anticipated to leverage strategic acquisitions to bolster its growth. The acquisition of Apogee Therapeutics, which is centered on therapies for immunological disorders, enhances AbbVie's product lineup and strategic positioning in the market. Analysts have noted that this move could be integral to AbbVie’s recovery process as it faces lower revenue from Humira.
New Drug Developments: ABBV-466 and Its Potential
Further underpinning AbbVie's resurgence is the promising data emerging from its drug pipeline, particularly from ABBV-466. This combination therapy that pairs Skyrizi with a second antibody, is showing strong efficacy in the treatment of Crohn's disease, achieving higher endoscopic remission rates than either drug on its own. The results have intrigued Wall Street and analysts alike, hinting at a potential new blockbuster in AbbVie’s arsenal. ABBV-466 could add to AbbVie's portfolio, building upon the company's prior success with Skyrizi. Positive clinical outcomes from the trials have led analysts to project that ABBV-466 might significantly enhance AbbVie’s market standing, echoing earlier sentiments about the strategic direction of the company and underscoring its commitment to research and development.

